Suppr超能文献

含防腐剂和不含防腐剂的眼科抗青光眼药物使用模式:一项横断面研究。

Use Pattern of Ophthalmic Antiglaucoma Agents with and without Preservatives: A Cross-Sectional Study.

作者信息

Valladales-Restrepo Luis Fernando, Oyuela-Gutiérrez María Camila, Delgado-Araujo Ana Camila, Machado-Alba Jorge Enrique

机构信息

Grupo de Investigación en Farmacoepidemiología y Farmacovigilancia, Universidad Tecnológica de Pereira-Audifarma S.A, Pereira 660003, Colombia.

Grupo de Investigación Biomedicina, Facultad de Medicina, Fundación Universitaria Autónoma de las Américas, Pereira 660003, Colombia.

出版信息

Pharmaceuticals (Basel). 2023 May 12;16(5):743. doi: 10.3390/ph16050743.

Abstract

BACKGROUND

Different drugs have been approved to reduce the intraocular pressure. However, most of them contain preservatives to maintain sterility and these can be toxic to the ocular surface. The aim was to determine the patterns of use of antiglaucoma agents and ophthalmic preservatives in a group of patients from Colombia.

METHODS

A cross-sectional study that identified ophthalmic antiglaucoma agents from a population database of 9.2 million. Sociodemographic and pharmacological variables were considered. Descriptive and bivariate analyses were performed.

RESULTS

A total of 38,262 patients were identified, with a mean age of 69.2 ± 13.3 years, and 58.6% were women. A total of 98.8% were prescribed antiglaucoma drugs in multidose containers. The most widely used were prostaglandin analogs (59.9%), especially latanoprost (51.6%) and β-blockers (59.2%). A total of 54.7% of patients received combined management, especially with fixed-dose combination (FDC) drugs (41.3%). A total of 94.1% used antiglaucoma drugs with preservatives (benzalkonium chloride, 68.4%).

CONCLUSIONS

The pharmacological treatment of glaucoma was very heterogeneous, but the most commonly used therapeutic groups were in accordance with the recommendations of clinical practice guidelines but with differences by sex and age. Most of the patients were exposed to preservatives, especially benzalkonium chloride, but the wide use of FDC drugs can minimize toxicity on the ocular surface.

摘要

背景

不同药物已被批准用于降低眼压。然而,它们中的大多数含有防腐剂以保持无菌状态,而这些防腐剂可能对眼表有毒性。目的是确定哥伦比亚一组患者中抗青光眼药物和眼科防腐剂的使用模式。

方法

一项横断面研究,从920万人口数据库中识别眼科抗青光眼药物。考虑了社会人口统计学和药理学变量。进行了描述性和双变量分析。

结果

共识别出38262名患者,平均年龄为69.2±13.3岁,58.6%为女性。98.8%的患者使用多剂量容器包装的抗青光眼药物。使用最广泛的是前列腺素类似物(59.9%),尤其是拉坦前列素(51.6%)和β受体阻滞剂(59.2%))。54.7%的患者接受联合治疗,尤其是使用固定剂量复方(FDC)药物(41.3%)。94.1%的患者使用含防腐剂(苯扎氯铵,68.4%)的抗青光眼药物。

结论

青光眼的药物治疗非常多样化,但最常用的治疗组符合临床实践指南的建议,但存在性别和年龄差异。大多数患者接触到防腐剂,尤其是苯扎氯铵,但FDC药物的广泛使用可将眼表毒性降至最低。

相似文献

1
Use Pattern of Ophthalmic Antiglaucoma Agents with and without Preservatives: A Cross-Sectional Study.
Pharmaceuticals (Basel). 2023 May 12;16(5):743. doi: 10.3390/ph16050743.
3
Ocular Surface Disease in Glaucoma: Effect of Polypharmacy and Preservatives.
Optom Vis Sci. 2015 Sep;92(9):e222-6. doi: 10.1097/OPX.0000000000000542.
5
Comparative cross-sectional analysis of the effects of topical antiglaucoma drugs on the ocular surface.
Adv Ther. 2013 Apr;30(4):420-9. doi: 10.1007/s12325-013-0021-8. Epub 2013 Apr 4.
6
Antiglaucoma drugs: The role of preservative-free formulations.
Saudi J Ophthalmol. 2011 Oct;25(4):389-94. doi: 10.1016/j.sjopt.2011.08.004. Epub 2011 Aug 28.
7
In vitro effects of preserved or preservative-free antiglaucoma medications on human complement system.
Curr Eye Res. 2003 Oct;27(4):253-9. doi: 10.1076/ceyr.27.4.253.16603.
8
Objective ocular surface tolerance in patients with glaucoma treated with topical preserved or unpreserved prostaglandin analogues.
Eur J Ophthalmol. 2019 Nov;29(6):645-653. doi: 10.1177/1120672118805877. Epub 2018 Oct 10.
9
Assessment of ocular surface disease in glaucoma patients with benzalkonium chloride-preserved latanoprost eye drops: a short-term longitudinal study.
Graefes Arch Clin Exp Ophthalmol. 2021 May;259(5):1243-1251. doi: 10.1007/s00417-020-05067-y. Epub 2021 Jan 12.
10
Toxicity evaluation of antiglaucoma drugs using stratified human cultivated corneal epithelial sheets.
Invest Ophthalmol Vis Sci. 2012 Aug 3;53(9):5154-60. doi: 10.1167/iovs.12-9685.

引用本文的文献

1
Research progress of corneal characteristics and changes in primary angle‑closure glaucoma (Review).
Biomed Rep. 2025 Feb 5;22(4):59. doi: 10.3892/br.2025.1937. eCollection 2025 Apr.

本文引用的文献

1
Overview of FDA Drug Approval and Labeling.
J Allergy Clin Immunol Pract. 2022 Dec;10(12):3051-3056. doi: 10.1016/j.jaip.2022.09.005.
2
Factors Associated with Non-Adherence to Glaucoma Treatment in a Korean Nationwide Survey.
Iran J Public Health. 2022 Jun;51(6):1259-1264. doi: 10.18502/ijph.v51i6.9669.
3
Updates on the Diagnosis and Management of Glaucoma.
Mayo Clin Proc Innov Qual Outcomes. 2022 Nov 16;6(6):618-635. doi: 10.1016/j.mayocpiqo.2022.09.007. eCollection 2022 Dec.
4
Glaucoma and Ocular Surface Disease: More than Meets the Eye.
Clin Ophthalmol. 2022 Nov 4;16:3641-3649. doi: 10.2147/OPTH.S388886. eCollection 2022.
5
Recent Trends in Treatment and Associated Costs of Primary Angle-Closure Glaucoma: A Retrospective Cohort Study.
Ophthalmol Glaucoma. 2023 May-Jun;6(3):308-315. doi: 10.1016/j.ogla.2022.10.002. Epub 2022 Oct 15.
6
Topical glaucoma medications - Clinical implications for the ocular surface.
Ocul Surf. 2022 Oct;26:19-49. doi: 10.1016/j.jtos.2022.07.007. Epub 2022 Jul 31.
7
Ocular Surface Disease and Anti-Glaucoma Medications: Various features, Diagnosis, and Management Guidelines.
Semin Ophthalmol. 2023 Feb;38(2):158-166. doi: 10.1080/08820538.2022.2094714. Epub 2022 Aug 1.
9
Primary Open-Angle Glaucoma Preferred Practice Pattern®.
Ophthalmology. 2021 Jan;128(1):P71-P150. doi: 10.1016/j.ophtha.2020.10.022. Epub 2020 Nov 12.
10
Topical Medication Therapy for Glaucoma and Ocular Hypertension.
Front Pharmacol. 2021 Dec 1;12:749858. doi: 10.3389/fphar.2021.749858. eCollection 2021.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验